Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Academic Article uri icon

Overview

publication date

  • November 1, 2018

Identity

PubMed Central ID

  • PMC6290878

Scopus Document Identifier

  • 85058593544

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdx807

PubMed ID

  • 29390043

Additional Document Info

volume

  • 29

issue

  • 11